Search

Your search keyword '"Jiunn-Song Jiang"' showing total 2 results
Start Over Author "Jiunn-Song Jiang" Publisher public library of science (plos)
2 results on '"Jiunn-Song Jiang"'

1. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.

Author

Wei-Wei Ng, Chen-Chun Lin, Ching-Yuan Cheng, Jiunn-Song Jiang, Shang-Jyh Kao, and Diana Yuwung Yeh

Subjects
Medicine, Science
Abstract

The sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) remains a matter of controversy. This cohort study analyzed the overall survival (OS) and progression-free survival (PFS) of afatinib compared with erlotinib and gefitinib first-line. EGFRm+, advanced NSCLC patients treated with either afatinib, erlotinib or gefitinib were retrospectively analyzed. A total of 107 patients were included. There was no statistically significant difference in PFS among the 3 groups. In the ≥ 60 years age group, the afatinib group had longer survival compared to the gefitinib group (p = 0.01). Median OS were 19.1, 22.9, and 35.6 months for gefitinib, erlotinib, and afatinib groups, respectively, with statistical significance between the gefitinib and afatinib groups (p = 0.009). Patients on afatinib also had longer median OS than erlotinib and gefitinib pooled together (35.5 versus 21.4 months; hazard ratio = 0.54, p = 0.016), despite similar median PFS. In conclusion, afatinib is a better choice compared to gefitinib or erlotinib for EGFRm+ patients. The OS obtained with afatinib is just 3 months shorter than osimertinib in the FLAURA trial. Direct comparison studies with osimertinib are still needed to determine optimal sequencing.

Published
2021
Full Text
View/download PDF

2. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study

Author

Jiunn-Song Jiang, Chen-Chun Lin, Diana Yu-Wung Yeh, Ching-Yuan Cheng, Shang-Jyh Kao, and Wei-Wei Ng

Subjects
Oncology, Male, Lung Neoplasms, Physiology, Afatinib, Kinase Inhibitors, Cancer Treatment, Artificial Gene Amplification and Extension, Biochemistry, Lung and Intrathoracic Tumors, Endocrinology, Epidermal growth factor, Carcinoma, Non-Small-Cell Lung, Medicine and Health Sciences, Osimertinib, heterocyclic compounds, Epidermal growth factor receptor, Enzyme Inhibitors, Multidisciplinary, biology, Middle Aged, Progression-Free Survival, Neoplasm Proteins, ErbB Receptors, Survival Rate, Deletion Mutation, Medicine, Female, Erlotinib, Tyrosine kinase, medicine.drug, Research Article, Clinical Oncology, medicine.medical_specialty, Science, Radiation Therapy, Tyrosine Kinase Inhibitors, Research and Analysis Methods, Gefitinib, Internal medicine, Growth Factors, medicine, Genetics, Humans, Lung cancer, Molecular Biology Techniques, Protein Kinase Inhibitors, Molecular Biology, neoplasms, Aged, Retrospective Studies, Endocrine Physiology, Epidermal Growth Factor, business.industry, Cancers and Neoplasms, Biology and Life Sciences, medicine.disease, Non-Small Cell Lung Cancer, respiratory tract diseases, Mutation, biology.protein, Enzymology, Amplification-Refractory Mutation System Analysis, Clinical Medicine, business
Abstract

The sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) remains a matter of controversy. This cohort study analyzed the overall survival (OS) and progression-free survival (PFS) of afatinib compared with erlotinib and gefitinib first-line. EGFRm+, advanced NSCLC patients treated with either afatinib, erlotinib or gefitinib were retrospectively analyzed. A total of 107 patients were included. There was no statistically significant difference in PFS among the 3 groups. In the ≥ 60 years age group, the afatinib group had longer survival compared to the gefitinib group (p = 0.01). Median OS were 19.1, 22.9, and 35.6 months for gefitinib, erlotinib, and afatinib groups, respectively, with statistical significance between the gefitinib and afatinib groups (p = 0.009). Patients on afatinib also had longer median OS than erlotinib and gefitinib pooled together (35.5 versus 21.4 months; hazard ratio = 0.54, p = 0.016), despite similar median PFS. In conclusion, afatinib is a better choice compared to gefitinib or erlotinib for EGFRm+ patients. The OS obtained with afatinib is just 3 months shorter than osimertinib in the FLAURA trial. Direct comparison studies with osimertinib are still needed to determine optimal sequencing.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results